explore -WSS

explore

author：explore 2025-10-02 22:15:35 - browse：5586

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Texas board proposes rules on abortion law emergency exemption

WSS

Judge denies Trump's request for new trial in E. Jean Carroll case

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Cancer, immunology, HIV research ensnared in fetal tissue politics

Texas board proposes rules on abortion law emergency exemption

Chinese researcher claims birth of first gene

'Patient friction coefficient' can gauge a clinical trial's patient burden

hotspot

explore

hotspot

Drug repurposing or repositioning? The language matters

Dementia risk linked to living in disadvantaged areas: Study

Anesthesiologist group: stop taking Ozempic before surgery

Yancopoulos of Regeneron works to expand Dupixent success

Trump demands the U.S. pay no more for drugs than other countries … again

US jobless claims fall again as labor market continues to flash strength

State Dept. review finds Biden bears some blame for Afghanistan failures

Chinese researcher claims birth of first gene

Trump demands the U.S. pay no more for drugs than other countries … again

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

hotspot

The stock market has soared this year, but will it last? Experts weigh in

How a Boston hospital is priming medical residents to use GPT

Delta passengers in Vegas fall sick while waiting on flight in triple

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Testing GLP

Wikipedia

leisure time

knowledge

leisure time